Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
03 Apr 2026, 16:34:34 UTC
Prior SEC filing
22 Oct 2025
Next SEC filing
08 Apr 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Douglas Barry, Attorney-in-Fact
Filing notes and source

Key filing fact

Michael R. Megna filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 03 Apr 2026.

Key facts

  • This page summarizes Michael R. Megna's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
  • 9 reported transactions and 6 derivative rows are listed below.
  • Accepted by SEC: 03 Apr 2026, 16:34.

Change

  • Previous filing in this sequence was filed on 22 Oct 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001464583 Primary reporting owner

Megna Michael R

Relationship
CHIEF ACCOUNTING OFFICER
Address
C/O KINIKSA PHARMACEUTICALS INT'L, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM
Signature
/s/ Douglas Barry, Attorney-in-Fact
Signature date
03 Apr 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Ordinary Share

Award

Transaction value
Shares
+372
Change %
+1.4%
Price
$24.16*
Shares after
27,418
Date
15 Jan 2026
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
Shares
+7,564
Change %
+28%
Price
Shares after
34,982
Date
01 Apr 2026
Ownership
Direct
Footnotes
F2
KNSA transaction

Class A Ordinary Share

Tax liability

Transaction value
Shares
-3,205
Change %
-9.2%
Price
$48.13*
Shares after
31,777
Date
01 Apr 2026
Ownership
Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Award

Transaction value
Shares
+14,600
Change %
Price
$0.000000*
Shares after
14,600
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
14,600
Exercise price
$48.13
Footnotes
F3
KNSA transaction Derivative

Restricted Share Unit

Award

Transaction value
Shares
+3,650
Change %
Price
$0.000000*
Shares after
3,650
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
3,650
Exercise price
Footnotes
F2, F4
KNSA transaction Derivative

Performance Share Unit

Award

Transaction value
Shares
+7,300
Change %
Price
$0.000000*
Shares after
7,300
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
73,000
Exercise price
Footnotes
F5, F6
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
Shares
-2,558
Change %
-50%
Price
$0.000000*
Shares after
2,557
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
2,558
Exercise price
Footnotes
F2, F7
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
Shares
-2,362
Change %
-33%
Price
$0.000000*
Shares after
4,725
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
2,362
Exercise price
Footnotes
F2, F8
KNSA transaction Derivative

Restricted Share Unit

Options Exercise

Transaction value
Shares
-2,644
Change %
-25%
Price
$0.000000*
Shares after
7,931
Date
01 Apr 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
2,644
Exercise price
Footnotes
F2, F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 9 footnotes

Footnote F1

The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2025 to January 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).

Footnote F2

Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.

Footnote F3

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2026.

Footnote F4

The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter.

Footnote F5

Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee.

Footnote F6

Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply.

Footnote F7

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023.

Footnote F8

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024.

Footnote F9

The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .